Most Recent
Maurice Blackburn owes State Street royalties for Fearless Girl replica, court hears
Intellectual Property August 6, 2019 1:32 pm By Christine Caulfield

US investment manager State Street Global Advisors claims it lost out on royalties when Maurice Blackburn commissioned an allegedly infringing replica of its iconic Fearless […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Want to test drive Lawyerly? Contact us to take a free trial.

BASF termite control patent invalid, court told
Intellectual Property July 9, 2019 3:50 pm By Miklos Bolza

Sherwood Chemicals wants to exterminate claims alleging it infringed two patents held by US chemical giant BASF for an underground termite control system, saying the […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Want to test drive Lawyerly? Contact us to take a free trial.

Teva, Boehringer settle inhaler capsule patent dispute
Intellectual Property June 19, 2019 2:56 pm By Miklos Bolza

Israeli drug giant Teva and German drug maker Boehringer Ingelheim have settled their dispute over a patented capsule used to deliver the medicine in Boehringer’s […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Want to test drive Lawyerly? Contact us to take a free trial.

Bayer faces appeals of IP Australia rulings on antiseptic patent
Intellectual Property June 4, 2019 3:24 pm By Miklos Bolza

Veterinary pharmaceutical companies Norbrook Laboratories and Merial have launched twin appeals of two IP Australia decisions allowing Bayer to amend a proposed patent for a […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Want to test drive Lawyerly? Contact us to take a free trial.

Novartis patent for oral form of top-selling MS drug obvious, IP Australia says
Intellectual Property May 13, 2019 12:31 pm By Miklos Bolza

A proposed Novartis patent for an oral form of its top-selling multiple sclerosis drug Gilenya is invalid for lack of inventive step, IP Australia has […]

Subscribe for instant access to all Lawyerly content.

Already a subscriber?

Lost your password?

Want to test drive Lawyerly? Contact us to take a free trial.